Discrete Oligomers and Polymers of Chloride Monohydrate Can Form in Encapsulated Environments: Structures and Infrared Spectra of [Cl
<sub>4</sub>
(H
<sub>2</sub>
O)
<sub>4</sub>
]
<sup>4−</sup>
and {[Cl(H
<sub>2</sub>
O)]
<sup>−</sup>
}
<sub>∞</sub>
作者:Rathiga Senthooran、Owen J. Curnow、Deborah L. Crittenden
DOI:10.1002/cplu.202100342
日期:2021.9
computationally-unstable in the gas phase which indicates that an encapsulated environment is essential for their isolation. DFT and DFTB calculations were carried out on gas-phase [Cl4(H2O)4]4− to assist the infrared assignments. Anharmonically-corrected B3LYP transition frequencies were in close agreement with experiment, but DFTB models were only appropriate for qualitative interpretation. Solid-state
[EN] PYRIDIN- 2 -AMIDES USEFUL AS CB2 AGONISTS<br/>[FR] PYRIDIN-2-AMIDES UTILES COMME AGONISTES DE CB2
申请人:HOFFMANN LA ROCHE
公开号:WO2012168350A1
公开(公告)日:2012-12-13
The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
Reaction of tetrakis(dimethylamino)ethylene with CF2Br2 in the presence of secondary amines, formation of N-trifluoromethyl-dialkylamines
作者:G. Pawelke
DOI:10.1016/s0022-1139(00)80138-4
日期:1991.4
R2NCF3 (R= Me (I),Et (II), i-Pr (III), i-Bu (IV); 2R = (CH3)2C-(CH2)3-C(CH3)2 (V) and(CH2)6 (VI) ) have been obtained from the corresponding secondaryamines R2NH with the reagent combination tetrakis(dimethylamino)ethylene/CF2Br2/(CH2)4SO2in moderate yields. The new N-trifluoromethylamineshave been characterized by elemental analyses, multi-nuclearNMR and vibrational spectra and the mechanism of formationis
The invention relates to a compound of formula (I)
wherein R
1
to R
4
are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
Provided herein are novel neuromodulatory compounds and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine and Parkinson's disease, using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT
1D
and/or the 5-HT
1B
receptor, without agonizing the 5-HT
2B
receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alpha
2A
and/or the alpha
2B
receptors using the compounds and compositions disclosed herein. In other embodiments, provided herein are methods of agonizing dopaminergic D
2
receptors and/or antagonizing or inhibiting activity of receptors such as the 5-HT
2
receptors using the compounds and compositions disclosed herein.